BioSpace News Archive

Kazia Therapeutics Limited is pleased to announce the appointment of John Friend , MD, as Chief Medical Officer.

LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced it will present two-year follow-up data for the Phase 1/2a study of LiPax in patients with non-muscle invasive bladder cancer (NMIBC) at the 22nd Annual Meeting of the Society of Urologic Oncology.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced the company will participate in two upcoming virtual investor conferences.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced the appointment of Richa Poddar to the role of chief commercial officer, effective Dec. 6, 2021.

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, reported third quarter 2021 financial results.

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, reported financial results for the third quarter ended September 30, 2021, and also provided an update on recent corporate and clinical developments.

Chinook Therapeutics, Inc. announced the closing of its upsized underwritten public offering of 9,538,572 shares of its common stock at a price to the public of $14.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 1,710,000 shares of its common stock.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company will participate in the 12th Annual Jefferies London Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference.

Evofem Biosciences, Inc., (NASDAQ: EVFM) (“Evofem” or the “Company”), today reported financial results for the three- and nine-month periods ended September 30, 2021.

Biostage, Inc., a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, announced its financial results for the three and nine months ended September 30, 2021.